Elevated levels of CHI3L1 were found in both the CSF and serum of MS patients (including CIS, RRMS, PPMS, and SPMS), suggesting that serum CHI3L1 levels might be used instead of CSF CHI3L1 levels as a potential diagnostic biomarker [71]. The gene discussed is CHI3L1; the disease is in situ carcinoma.